Intellectual Property AlertToday the Federal Circuit reversed a district court’s JMOL and held that claims to a method of treating headaches using a genus of antagonistic anti-CGRP antibodies satisfied both the written description and enablement requirements. In particular, the court held that the prior art evidence demonstrates the genus was well known, methods of making the antibodies were routine and “critically” all of the antibodies in the genus worked in the method of treatment—even the di...
Continue Reading
Sign up for FREE to read the full article and access 132K+ alternative investment headlines.
Alternative Investment News